Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guide...Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guideline by Conroy et al.(1)points to important advances in pancreatic cancer therapy that were made since the previous edition from 2015(2).According to the American Cancer Society the overall five-year survival for all stages of PDAC has improved from 5%some 30 years ago to 13%in the present day.The major thrust lies in greatly improved outcomes for resectable pancreatic cancer with 5-year survival increasing from 5-10%at the beginning of this period to 30-50%due to technical improvements in surgery along with combination adjuvant chemotherapy.展开更多
The emergence of multi-drug resistance makes bacterial infection a major threat to public health and economy.The formation of bacterial biofilms is one of the main reasons of bacterial resistance.The complexity of che...The emergence of multi-drug resistance makes bacterial infection a major threat to public health and economy.The formation of bacterial biofilms is one of the main reasons of bacterial resistance.The complexity of chemical composition and physical structure makes the elimination of mature biofilms a difficult problem.The highly antibiotic resistant property of biofilms urgently calls for potent antimicrobial agents and novel antibiofilm strategies.Researchers have made a lot of efforts in this field.Here we review the current strategies to eliminate mature biofilms and progress in related drug delivery nanosystems,with the aim of inspiring researchers to design new antibiofilm systems.展开更多
文摘Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guideline by Conroy et al.(1)points to important advances in pancreatic cancer therapy that were made since the previous edition from 2015(2).According to the American Cancer Society the overall five-year survival for all stages of PDAC has improved from 5%some 30 years ago to 13%in the present day.The major thrust lies in greatly improved outcomes for resectable pancreatic cancer with 5-year survival increasing from 5-10%at the beginning of this period to 30-50%due to technical improvements in surgery along with combination adjuvant chemotherapy.
基金the Natural Science Foundation of Shanghai(18ZR1410300)the National Natural Science Foundation of China(No.21861162010,21774031,31800801)+3 种基金Program of Shanghai Academic/Technology Research Leader(20XD1421400)the National Key Research and Development Program of China(2016YFC1100401)Research Program of State Key Laboratory of Bioreactor Engineeringthe Fundamental Research Funds for the Central Universities(No.22221818014,50321041917001)。
文摘The emergence of multi-drug resistance makes bacterial infection a major threat to public health and economy.The formation of bacterial biofilms is one of the main reasons of bacterial resistance.The complexity of chemical composition and physical structure makes the elimination of mature biofilms a difficult problem.The highly antibiotic resistant property of biofilms urgently calls for potent antimicrobial agents and novel antibiofilm strategies.Researchers have made a lot of efforts in this field.Here we review the current strategies to eliminate mature biofilms and progress in related drug delivery nanosystems,with the aim of inspiring researchers to design new antibiofilm systems.
